000403 Stock Overview
Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in research, development, production, and sales of blood products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Pacific Shuanglin Bio-pharmacy Co., LTD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥20.94 |
| 52 Week High | CN¥30.64 |
| 52 Week Low | CN¥19.46 |
| Beta | 0.48 |
| 1 Month Change | -6.06% |
| 3 Month Change | 0.38% |
| 1 Year Change | -22.87% |
| 3 Year Change | -24.51% |
| 5 Year Change | 22.26% |
| Change since IPO | 2,123.71% |
Recent News & Updates
Benign Growth For Pacific Shuanglin Bio-pharmacy Co., LTD (SZSE:000403) Underpins Its Share Price
Nov 25
If EPS Growth Is Important To You, Pacific Shuanglin Bio-pharmacy (SZSE:000403) Presents An Opportunity
Oct 10Recent updates
Benign Growth For Pacific Shuanglin Bio-pharmacy Co., LTD (SZSE:000403) Underpins Its Share Price
Nov 25If EPS Growth Is Important To You, Pacific Shuanglin Bio-pharmacy (SZSE:000403) Presents An Opportunity
Oct 10Pacific Shuanglin Bio-pharmacy Co., LTD's (SZSE:000403) Shares May Have Run Too Fast Too Soon
Aug 16We Think Pacific Shuanglin Bio-pharmacy (SZSE:000403) Can Stay On Top Of Its Debt
Jul 22Is Now The Time To Put Pacific Shuanglin Bio-pharmacy (SZSE:000403) On Your Watchlist?
May 24Shareholder Returns
| 000403 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -3.4% | -1.9% | -1.2% |
| 1Y | -22.9% | -16.2% | 11.8% |
Return vs Industry: 000403 underperformed the CN Biotechs industry which returned -16.2% over the past year.
Return vs Market: 000403 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 000403 volatility | |
|---|---|
| 000403 Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 000403 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 000403's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 2,426 | Xiankui Rong | www.slbiop.com |
Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in research, development, production, and sales of blood products in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies patient immunoglobulin, and human coagulation factor. addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; and electronic product information consultation.
Pacific Shuanglin Bio-pharmacy Co., LTD Fundamentals Summary
| 000403 fundamental statistics | |
|---|---|
| Market cap | CN¥15.27b |
| Earnings (TTM) | CN¥828.65m |
| Revenue (TTM) | CN¥2.84b |
18.4x
P/E Ratio5.4x
P/S RatioIs 000403 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 000403 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.84b |
| Cost of Revenue | CN¥1.38b |
| Gross Profit | CN¥1.47b |
| Other Expenses | CN¥637.01m |
| Earnings | CN¥828.65m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.14 |
| Gross Margin | 51.53% |
| Net Profit Margin | 29.13% |
| Debt/Equity Ratio | 7.3% |
How did 000403 perform over the long term?
See historical performance and comparisonDividends
1.4%
Current Dividend Yield31%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 00:58 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pacific Shuanglin Bio-pharmacy Co., LTD is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Feifei Xu | China Merchants Securities Co. Ltd. |
| Zhu Chen | Citic Securities Co., Ltd. |
| Kai Wang | Citic Securities Co., Ltd. |